Clinical experience with piribedil in chronic cerebrovascular disease with cognitive impairment
https://doi.org/10.14412/2074-2711-2019-4-100-103
Abstract
Objective: to evaluate the effect of piribedil on cognitive functions in elderly patients with chronic cerebrovascular disease (CCVD) and cognitive impairment (CI).
Patients and methods. A total of 67 patients aged 60-75 years with CCVD and CI were examined. A control group included 32 patients who had received basic therapy with antihypertensive and, if indicated, lipid-lowering and antithrombotic drugs. A study group consisted of 35 patients who additionally took piribedil 50 mg after evening meals for 3 months. Neuropsychological examination was made before and after a treatment cycle.
Results and discussion. After 3 months, only the piribedil group showed a significant neuropsychological improvement (p<0.05-0.001). There were statistically significant differences in the measures of short-term (5.9±0.5 and 4.27±0.5 words; p<0.05) and long-term (6.4±0.8 and 4.16±0.5 words; p<0.05) memories, correction task (38.4±0.8 and 49.1±0.1 errors; p<0.001), attentiveness (421.0±0.9 and 406.0±0.6 sec; p<0.001), and work efficiency (16.3±0.9 and 12.3±1.2 sec; p<0.05). The investigation revealed that the drug had a good tolerability, neither adverse events nor drug-drug interactions.
Conclusion. When used in CCVD and CI, piribedil 50 mg once daily for 3 months is able to improve cognitive functions in elderly patients, which indicates that it is feasible to use the drug in combined therapy with essential (antihypertensive, lipid-lowering, antithrombotic) medicines.
About the Authors
E. V. Moroz
Vladivostok Branch, Far Eastern Research Center for Physiology and Respiratory Pathology, Research Institute of Medical Climatology and Medical Rehabilitation
Russian Federation
73G, Russkaya St., Vladivostok 690105
Russian Federation
73G, Russkaya St., Vladivostok 690105
T. A. Zakharycheva
Far Eastern State Medical University, Ministry of Health of Russia
Russian Federation
35, Muravyev-Amursky St., Khabarovsk 680000
Russian Federation
35, Muravyev-Amursky St., Khabarovsk 680000
M. V. Antonyuk
Vladivostok Branch, Far Eastern Research Center for Physiology and Respiratory Pathology, Research Institute of Medical Climatology and Medical Rehabilitation
Russian Federation
73G, Russkaya St., Vladivostok 690105
Russian Federation
73G, Russkaya St., Vladivostok 690105
References
1. Kadykov AS, Manvelov LS, Shakhporonova NV. Khronicheskie sosudistye zabolevaniya golovnogo mozga: distsirkulyatornaya entsefalopatiya [Chronic vascular diseases of the brain: dyscirculatory encephalopathy]. Moscow: GEOTAR-Media; 2014.
2. Gusev EI, Konovalov AN, Skvortsova VI, editors. Nevrologiya: natsional'- noe rukovodstvo [Neurology: a national guide]. 2nd ed. Vol. 1. Moscow: GEOTAR-Media; 2018. 880 p.
3. Budilova EV, Lagutin MB, Migranova LA. Gender differences in life expectancy and morbidity of the Russian population. Klinicheskaya gerontologiya. 2016;22(9):8-9. (In Russ.)
4. Ostroumova TM, Parfenov VA, Ostroumova OD. Hypertension and cognitive impairment: the standpoint of evidence-based medicine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(4):70-6. (In Russ.) doi: 10.14412/2074-2711-2017-4-70-76
5. World Health Organization. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012.
6. Gusev EI, Chukanova EI. Modern pathogenetic aspects of formation of chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(3):4-8. (In Russ.)
7. Levin OS. Dyscirculatory encephalopathy: anachronism or clinical reality. Sovremennaya terapiya v psikhiatrii i nevrologii. 2012;(3):40-6. (In Russ.)
8. Yakhno NN, Zakharov VV, Lokshina AB. The syndrome of moderate cognitive disorders at dyscirculatory encephalopathy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005; 105(2):13-7. (In Russ.)
9. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.
10. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18. doi: 10.1097/WAD.0000000000000034.
11. Parfenov VA. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3S):61-7. (In Russ.) doi: 10.14412/2074-2711-2019-3S-61-67
12. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016 Aug;30(8): 703-17. doi: 10.1007/s40263-016-0360-5.
13. Nagaraia D, Jayashree S. Randomised study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry. 2001 Sep;158(9):1517-9.
14. Zakharov VV, Lokshina AB. The use of the drug pronoran (piribedil) in mild cognitive disorders in elderly patients with dyscirculatory encephalopathy. Nevrologicheskii zhurnal. 2004; (2):30-5. (In Russ.)
15. Zakharov VV. Prevalence and treatment of cognitive disorders in the neurological clinic (Results of the allRussian study «PROMETHEUS»). Consilium Medicum. 2008;10(2):25-9. (In Russ.)
16. Yakhno NN, Zakharov VV, Strachunskaya EYa, et al. Treatment of non-Dement cognitive impairment in patients with hypertension and cerebral atherosclerosis (according to the Russian multicenter study «FUETE»). Nevrologicheskii zhurnal. 2012;(4):49-55. (In Russ.)
17. Belova AN. Shkaly, testy i oprosniki v nevrologii i neirokhirurgii [Scales, tests and questionnaires in neurology and neurosurgery]. 3rd ed. Moscow: Prakticheskaya meditsina; 2018. 696 p.
18. Zakharov VV, Voznesenskaya TG. Nervno-psikhicheskie narusheniya: diagnosticheskie testy [Нервно-психические нарушения: диагностические тесты]. 2nd ed. Moscow: MEDpress-inform; 2013. 320 p.
19. Antonyuk MV, Zakharycheva TA, Moroz EV. Otsenka reabilitatsionnogo potentsiala u patsientov starshei vozrastnoi gruppy s distsirkulyatornoi entsefalopatiei: posobie dlya vrachei [Assessment of rehabilitation potential in patients of older age group with dyscirculatory encephalopathy: Handbook for doctors]. Vladivostok; 2019. 27 p.
20. Zakharov VV, Gromova DO. Modern approaches to the management of patients with mild cognitive impairment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(3):107-12. (In Russ.)
21. Peihua L, Jianqin W. Clinical effects of piribedil in adjuvant treatment of Parkinson's Disease: A meta-analysis. Open Med (Wars). 2018 Jul 10;13:270-277. doi: 10.1515/med-2018-0041. eCollection 2018.
22. Wang W, Liu L, Chen C, et al. Protective effects of dopamine D2/D3 receptor agonist piribedil on learning and memory of rats exposed to global cerebral ischemia-reperfusion. Neurosci Lett. 2018 Sep 25;684:181-186. doi: 10.1016/j.neulet.2018.08.011. Epub 2018 Aug 11.
23. Verbitskaya SV, Parfenov VA, Reshetnikov VA, et al. Post-stroke cognitive impairment (results of a 5-year follow-up). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):37-42. (In Russ.) doi: 10.14412/2074-2711-2018-1-37-42
Review
For citations:
Moroz EV, Zakharycheva TA, Antonyuk MV. Clinical experience with piribedil in chronic cerebrovascular disease with cognitive impairment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(4):100-103. (In Russ.) https://doi.org/10.14412/2074-2711-2019-4-100-103
Views:
811
Email this article 